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Background: Hepatitis B virus (HBV) infection is a serious public health problem worldwide. This study aimed to
investigate the relationship between serum alpha-fetoprotein (AFP) levels and pathological stages of liver biopsy in
patients with chronic hepatitis B (CHB).
Methods: The study included 619 patients who were diagnosed with CHB from March 2005 to December 2011.
AFP levels were measured by electrochemiluminescence. Liver biopsy samples were classified into five levels of
inflammation (G) and fibrosis (S) stages, according to the Chinese guidelines for prevention and treatment of viral
hepatitis. Two multivariable ordinal regression models were performed to determine associations between AFP,
GGT, and APRI (AST/PLT ratio) and stages of inflammation and fibrosis.
Results: Significant positive and moderate correlations were shown between AFP levels and inflammation stages
and between AFP levels and fibrosis stages (ρ = 0.436 and 0.404, p < 0.001). Median values of AFP at liver fibrosis
stages S0-1, S2, S3, and S4 were 3.0, 3.4, 5.4, and 11.3 ng/ml, respectively, and median APRI (AST/PLT ratio) was 0.41.
Receiver operating characteristic (ROC) curve analyses revealed that the areas under the curves (AUCs) were 0.685,
0.727, and 0.755 (all p <0.001) for judging inflammation stages of G ≥ 2, G ≥ 3, G = 4 by AFP; and 0.691, 0.717, and
0.718 (all p <0.001) for judging fibrosis stages of S ≥ 2, S ≥ 3, and S = 4 by AFP. APRI levels showed significant
positive and moderate correlations with inflammation stages (ρ = 0.445, p < 0.001). AST, GGT, and APRI levels showed
significant positive but very weak to weak correlations with fibrosis stages (ρ = 0.137, 0.237, 0.281, p < 0.001).
Conclusions: Serum AFP levels increased as pathological levels of inflammation and fibrosis increased in CHB patients.
Our data showed the clinical significance of serum AFP levels in diagnosing liver inflammation and fibrosis. Assessment
of liver pathology may be improved by creating a predictive mathematical model by which AFP levels with other
biomarkers.
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Hepatitis B virus (HBV) infection is a serious public
health problem. The World Health Organization estimates
that 2 billion people are exposed to HBV annually and
more than 350 million are chronically infected worldwide
[1]. While most chronically infected individuals remain
asymptomatic carriers, many others develop significant
hepatic disease. China reports having 93 million HBV* Correspondence: doctordong@126.com; doctorjjj@sina.cn
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reproduction in any medium, provided the orcarriers and 20 million people infected with chronic
hepatitis B (CHB) [2]. In China, 80% hepatocellular
carcinoma (HCC) is HBV-related, and more than 350
000 patients diagnosed annually [1]. CHB is a slow,
progressive disease characterized by liver fibrosis [3]. Host
immune response and HBV gene mutations may influence
the development and severity of liver fibrosis [4].
Liver biopsy has been widely accepted as the gold
standard for diagnosing and grading liver inflammation
and fibrosis [5]. Liver fibrosis is the natural wound healing
process of necroinflammation caused by chronic HBV
infection, and the pathogenic process leading to cirrhosisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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is difficult, and even with limitations like sampling
variations, observer error and complications [7], biopsy is
still recommended for assessing fibrosis severity and
identifying patients at risk for HCC and cirrhosis [8].
Biopsy also differentiates immune tolerance from failed
immune clearance, which may predict a poorer response
to antiviral treatment [6]. However, non-invasive methods
originally validated in patients with chronic hepatitis C,
are being used increasingly to evaluate CHB. Biological
approaches quantifying biomarkers in serum samples [7]
or physical approaches applying ultrasound or magnetic
resonance to assess liver stiffness [8] have been used to
complement liver biopsy. Serum biomarkers of liver
inflammation and fibrosis include indirect markers,
such as prothrombin index, platelet count and aspartate
aminotransferase (AST)/alanine aminotransferase (ALT)
ratio, and AFP levels, all associated with fibrosis [9,10]; or
direct markers, including hyaluronic acid [11], matrix
metalloprotein (MMP) [7], and collagens such as
procollagen III and collagen IV [9,10] that directly reflect
physical properties of the hepatic extracellular matrix.
Advantages of these tests include availability and reprodu-
cibility across laboratories [12]; the main disadvantage is
that they are not liver-specific and results may be influ-
enced by comorbid conditions, requiring critical review
for false positive and false negative results [9,10].
AFP is a fetal protein produced in the yolk sac and
liver of the developing fetus. Its molecular weight is
between that of albumin and α1-globulin, suggesting an
early form of albumin [13]. Serum AFP was reported to
be a tumor marker for HCC as early as 1963 [14].
Although AFP is not specific for HCC, elevated AFP
levels are seen in chronic liver disease, especially viral
hepatitis, and non-hepatic malignancies such as pancreatic,
gastric, biliary and germ cell tumors [13]. Determination of
AFP levels has been used to monitor HCC onset and
progression, evaluate effectiveness of curative treatment,
and predict outcomes [15]. AFP is a useful screening tool
for HCC in developing countries where HCC prevalence
is high and CHB infection is its major risk factor [16].
High levels of AFP (>400 ng/ml) are strongly predictive
for HCC. AFP can be used indirectly as an index to
indicate fibrosis stage in chronic hepatitis C virus
infection [17,18]. However, it is not clear if AFP levels
are correlated with ongoing liver damage and repair
in chronic liver disease such as CHB.
Few studies have been conducted to evaluate liver
cirrhosis by analyzing AFP levels or evaluating associations
between AFP levels and fibrosis stages. We hypothesized
that analyzing serum AFP levels at different stages of
inflammation and fibrosis would clarify the diagnostic value
of AFP in predicting the grade and stage of liver pathology.
This study aimed to determine the subclinical significanceof low serum AFP levels by investigating the relationship
between serum AFP levels and different inflammation and
fibrosis stages in CHB patients.
Methods
Patients
This retrospective cross-sectional study included a total
of 619 consecutive patients older than 12 years with
CHB who were admitted to the First Affiliated Hospital
of Fujian Medical University from March 2005 to
December 2011. CHB was defined as HBsAg positivity for
at least 6 months, serum HBV DNA above 2000 IU/ml
(or 104 copies/ml), and alanine aminotransferase (ALT)
levels above the upper limit of normal, 40 IU/ml.
Patients with other types of viral hepatitis, alcoholic liver
disease, decompensated cirrhosis, autoimmune hepatitis,
concurrent infection with human immunodeficiency virus
(HIV), hereditary liver diseases, and drug-induced liver
injury were excluded. Based on the 2009 AASLD recom-
mendations, initial screening for HCC should be done
using B-mode ultrasound, and MRI scan and enhance-
ment should be adopted to exclude canceration of liver
nodules when necessary. In this study, all study subjects
underwent at least one B-mode ultrasound examination
prior to liver biopsy. Patients with AFP levels > 200 ng/ml
underwent CT/MRI scan with enhancement, and all
patients diagnosed with hepatocellular carcinoma were
excluded. Patients with moderate to severe fatty liver
(as revealed by B-mode ultrasound) were also excluded to
prevent any possible bias. All included patients had not
received any antiviral therapy prior to liver biopsy. Serum
and liver biopsy samples were collected from all patients
within 7 days after hospital admission.
The internal review board of First Affiliated Hospital
of Fujian Medical University reviewed and approved the
study protocol. Enrolled patients were deidentified, only
their applicable data were reviewed, so signed informed
consent was waived.
Methods
Liver biopsy and histopathology
All patients underwent liver biopsy using the Cardinal
18G Tru-Cut® Biopsy Needle (CardinaHealth; Dublin, OH)
under the guidance of Doppler ultrasound (ACUSON
Aspen Color Doppler Ultrasound, Siemens Medical
Solutions, Malvern, PA, USA). All biopsies were performed
by different experienced doctors, each of whom had
performed the procedure more than 20 times. All
procedures were performed under the guidance of a
B-mode ultrasound. Hepatic tissue samples which were
1.5- 2 cm in length or longer, were fixed in 4% neutral
formalin, paraffin imbedded, and serially sectioned to stain
with Hematoxylin-Eosin (HE), collagen, reticulum fiber
and immunohistochemical staining. Collagen staining was
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staining was done by Gomori staining (IHC World
Life Science Products, Woodstock, MD, USA). Standard
indirect labeling techniques for immunohistochemical
staining were applied using antibodies against components
of HBsAg and HBcAg as included in the 9000 Polymer
Detection System for Immuno-Histological Staining
(GBI Company, USA) (Figure 1). Antibodies were detected
with 3-amino-9-ethyl-carbazole substrate kit (Zymed
Laboratories, Inc. USA). All films were independently
reviewed by at least two pathologists.
Pathological diagnosis of liver disease was based on
the Programme of Prevention and Cure for Viral
Hepatitis, which was developed by the Society of
Infectious Diseases and Parasitology and the Chinese
Society of Hepatology of the Chinese Medical Association
and has been widely used in China since 2000 [19].
Patients’ biopsy samples were classified separately into
5 levels of inflammation (G) and fibrosis (S) stages
expressed as G 0 ~ 4 and S 0 ~ 4, as previously described
[6]. The key features of liver inflammation and fibrosis
stages are shown in Table 1.Laboratory examinations
Venous blood was collected from all patients to detect
and quantify serum AFP. Serum AFP was measured
quantitatively by electrochemiluminescence as previ-
ously described [20]. Electrochemiluminescence was
done using an autoanalyzer (Modular Analytics E170
Immunology Analyzer, Roche Diagnostics, USA), with
the normal reference value of 0 ~ 13.6 ng/ml and an
upper limit of detection of 1210 ng/ml. The normal
AFP level was defined as 0 ~ 15 ng/mL as previously
determined [3].Figure 1 Positive HBcAg signals on CHB patient biopsy. Detection
of HBcAg levels by anti-HBc as first antibody using immunohistochemical
staining, 100X magnification.Statistical analysis
Age was normally distributed and presented as mean with
standard deviation. AFP was non-normally distributed
and presented as median with inter-quartile range. Other
categorical data were presented as count and percentage.
Receiver operating characteristic (ROC) curves were
employed to obtain areas under the curve (AUC), sensitiv-
ity, and specificity. Spearman’s rank correlation coefficient
(ρ) was performed to evaluate correlations between AFP,
AST, ALT, and GGT versus liver inflammation and fibrosis
stages. Two multivariable ordinal regression models were
performed to show the associations between AFP, GGT,
and APRI (AST/PLT ratio) and inflammation and fibrosis
stages, after controlling for age and gender. All statistical
assessments were two sided and evaluated at the 0.05 level
of significance. Statistical analyses were performed using
SPSS 15.0 statistics software (SPSS Inc, Chicago, IL).
Results
Demographic characteristics
A total of 619 patients with CHB were recruited into
this study. The mean age of the patients was 38.9 years
(range from 13 to 71 years). The study population
comprised 506 males (81.7%) and 113 females (18.3%), of
whom 62.5% and 53.6% had inflammation and fibrosis
in stages 3–4, respectively (Table 2). There were no
significant differences in AFP levels between males
and females either by the two independent samples t-test or
the nonparametric Mann–Whitney test (data not shown).
Median AFP, AST, ALT and GGT values were 4.7 ng/mL,
63 U/L, 93 U/L and 54 U/L, respectively. The median APRI
was 0.41. (Table 2). Representative result of HBV infection
is shown in Figure 1.
Correlations of AFP levels versus liver inflammation and
fibrosis stages
Our data showed that the log AFP median levels
increased with inflammation and fibrosis stages
(Figure 2). The median values of AFP at liver inflamma-
tion stages of G0-1, G2, G3, and G4 were 2.7, 3.1, 5.5, and
24.3 ng/ml, respectively. Spearman’s rank correlation coef-
ficient showed significant positive and moderate correla-
tions between AFP and inflammation stages (ρ = 0.436,
p < 0.001). The median values of AFP at liver fibrosis
stages S0-1, S2, S3, and S4 were 3.0, 3.4, 5.4, and 11.3 ng/ml,
respectively. Spearman’s rank correlation coefficient
showed significant positive and moderate correlations
between AFP and fibrosis stages (ρ = 0.404, p < 0.001).
ALT, AST, and GGT levels also showed significant positive
but weak correlations with inflammation stages (ρ = 0.271,
0.393, 0.361, p < 0.001). APRI level showed significant
positive and moderate correlations with inflammation
stages (ρ = 0.445, p < 0.001). AST, GGT, and APRI
levels showed significant positive but very weak to
Table 1 Key features of liver inflammation and fibrosis stages*
Liver inflammation stages(G) Liver fibrosis stages(S)
Stage Portal area In lobule Stage Fibrosis
0 None None 0 None
1 Lymphopoiesis within portal area Hepatocyte hydropic or ballooning degeneration,
with/without spotty or focal necrosis
1 Mild fibrosis without septa
2 Mild piecemeal necrosis Spotty or focal necrosis, formation of acidophilic
bodies
2 Moderate fibrosis with few septa
3 Moderate piecemeal necrosis Severe degeneration and necrosis,with formation
of necrosis bridge
3 Severe fibrosis with numerous septa, but with
no sign of false lobules
4 Severe piecemeal necrosis Severe necrosis bridge,multiple lobular necrosis 4 Formation of false lobules
*Society of Infectious Diseases and Parasitology and Society of Hepatology, Chinese Medical Association (6).
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0.237, 0.281, p < 0.001) (Table 3).
Diagnostic value of AFP in dichotomizing liver
inflammation stages
After controlling for age and gender, the ordinal regres-
sion model showed that higher AFP and APRI levels
were significantly associated with higher inflammation
stages. The odds of higher stages to lower stages
increased with increasing levels of AFP and APRI (odds
ratios of 1.60 and 1.88 respectively; both p < 0.001). There
was no significant association between GGT levels
and inflammation stage (Table 4).
ROC curve analyses revealed that AUCs were 0.685,
0.727, and 0.755 (all p <0.001) for judging inflammationTable 2 Summary of patients’ characteristics
N = 619
Age1 (years) 38.9 ± 11.5
Gender Male 506 (81.7%)
Female 113 (18.3%)








AFP (ng/ml)2 4.7 (2.5, 13.7)
ALT (U/L)2 93.0 (46.0, 241.0)
AST (U/L)2 63.0 (37.0, 135.0)
GGT (UL)2 54.0 (31.0, 98.0)
APRI (AST/PLT ratio)2 0.41 (0.21, 0.83)
Two subjects with inflammation stage 0, and 80 subjects with inflammation
stage 1 were combined into one group; 27 subjects with fibrosis stage 0, and
124 subjects with fibrosis stage 1 were combined into one group.
1Data presented as mean with standard deviation. 2Data presented as median
with inter-quartile range. Other data are presented as count and percentage.stages of G ≥ 2, G ≥ 3, and G = 4 by AFP levels, and
were 0.741, 0.746, and 0.714 for judging inflammation
stages of G ≥ 2, G ≥ 3, and G = 4 by APRI levels. The
AUCs of AFP and APRI for judging inflammation stages
of G ≥ 2, G ≥ 3, and G = 4 did not differ from each
other significantly (all p > 0.05) (Table 5). In addition,
Figure 2A showed that 88.1% (54.8 + 33.3) of patients with
AFP levels between 13.6-27.2 ng/ml had inflammation
stages 3–4, while 50% of those with AFP levels >27.2 ng/ml
had inflammation stage 4.
Diagnostic value of AFP in dichotomizing liver fibrosis
stages
After controlling for age and gender, the ordinal regression
model showed that higher AFP and APRI levels were
significantly associated with higher fibrosis stages. The odds
of higher stages to lower stages increased with increasing
AFP and APRI values (odds ratios of 1.70 and 1.43;
p < 0.001). There was no significant association between
GGT levels and fibrosis stages (Table 4).
ROC curve analyses revealed that AUCs were 0.691,
0.717, and 0.718 (all p <0.001) for judging fibrosis stages
of S ≥ 2, S ≥ 3, and S = 4 by AFP levels. The AUCs of
AFP for judging fibrosis stages of S ≥ 3 and S = 4 (0.717
and 0.718, respectively) were significantly higher than
those of APRI (0.649 and 0.618, respectively; p = 0.007
and p < 0.001) (Table 5). In addition, 81.4% (26.2 + 45.2)
of patients with AFP levels between 13.6-27.2 ng/ml
had fibrosis stages 3–4, and 66.7% of those with AFP
levels >27.2 ng/ml had fibrosis stage 4 (Figure 2B).
Discussion
Results of this study indicated that the extent of liver
damage in CHB patients had an obvious effect on
AFP serum levels. There were significant positive and
moderate correlations between AFP and inflammation
stages and between AFP and fibrosis stages. AFP also
had a significant weak to moderate correlation with AST,
ALT and GGT values (Spearman’s correlation coefficients
were 0.22, 0.331, and 0.445, respectively; all p < 0.001).
Overall, as pathological levels of inflammation and fibrosis
Figure 2 The distribution of AFP vs. inflammation stage (A) and fibrosis stage (B). The upper limit of AFP normal range is 13.6 ng/ml,
patients were divided into three groups by AFP levels according to normal (0–13.6), 1–2 upper limit of AFP normal range (13.6-27.2), and more
than 2 upper limit of AFP normal range (>27.2).
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also increased.
Age and gender had little influence on changes in
serum AFP levels in this study. Approximately 70% of
CHB patients in China are infected via mother-to-child
vertical transmission, making it difficult to estimate the
median duration of CHB infection. Since the initial
detection of CHB infection does not represent the
start of infection, we used age to replace the duration
of infection. Ninety percent of those infected in
infancy, 50% who are infected in childhood, and even
fewer over the next years of young adulthood will
become chronically infected, with a high life-time risk
of developing HCC [21]. Liver pathology helps to
determine prognosis, as well as to determine who should
receive antiviral therapy [22]. Patients admitted to our
medical center were preparing for antiviral therapy andTable 3 Correlations of AFP, ALT, AST, GGT, and APRI with in
AFP (ng/ml) ALT (U/L)
Inflammation stage 0-1 2.7 (1.6, 5.2) 49.0 (29.0, 94
2 3.1 (2.1, 4.7) 85.5 (41.0, 15
3 5.5 (2.9, 13.5) 114.0 (51.0, 28
4 24.3 (4.9, 108.2) 132.5 (61.0, 30
Spearman's ρ 0.436* 0.271*
Fibrosis stage 0-1 3.0 (1.9, 5.2) 78.0 (35.0, 17
2 3.4 (2.3, 6.1) 113.5 (57.5, 28
3 5.4 (2.9, 16.6) 120.0 (51.0, 32
4 11.3 (3.8, 59.5) 84.0 (44.0, 18
Spearman's ρ 0.404* 0.021
Data are presented by median with IQR. *P-value < 0.001.the aim of liver biopsy in these cases was to clarify the
pathological status of the active CHB phase. Based on
patient selection, inflammation and fibrosis stages increased
with age, and so did AFP levels.
We showed that serum APRI values were significantly
associated with inflammation stages. We excluded serum
AST and ALT values from the multivariate analysis due
to its co-linearity with APRI values. Importantly, we
found that AFP levels increased as inflammation stages
progressed. The median serum AFP values in patients at
G0-G3 were within the normal range, while patients at
G4 had a significant elevation of AFP median values.
The correlation coefficient between AFP levels and
inflammation stages (0.436) showed a moderate positive
association between AFP levels and inflammation
stages in CHB patients. Marked changes in serum
AFP are not expected with light liver inflammationflammation and fibrosis stages
AST (U/L) GGT (UL) APRI (AST/PLT ratio)
.0) 31.0 (24.0, 58.0) 33.0 (20.0, 62.0) 0.17 (0.11, 0.40)
5.0) 48.5 (32.0, 85.0) 38.5 (27.0, 63.0) 0.26 (0.15, 0.49)
4.0) 79.0 (42.0, 148.0) 57.0 (35.0, 96.0) 0.52 (0.27, 0.89)
6.0) 97.0 (56.0, 172.0) 90.0 (58.0, 144.0) 0.73 (0.42, 1.50)
0.393* 0.361* 0.445*
1.0) 44.0 (29.0, 88.0) 38.0 (23.0, 64.0) 0.25 (0.13, 0.49)
1.0) 74.5 (43.5, 136.0) 52.0 (30.0, 83.0) 0.40 (0.21, 0.76)
4.0) 75.0 (41.0, 169.0) 61.0 (32.0, 106.0) 0.53 (0.22, 1.14)
7.0) 67.0 (41.0, 131.0) 66.0 (40.0, 118.0) 0.54 (0.29, 1.02)
0.137* 0.237* 0.281*
Table 4 Multivariable ordinal regression models for inflammation stage and fibrosis stage











stage 0/stage 1-4 −5.16 (−6.96, −3.37) 0.01 (0.00, 0.03) <0.001 −2.44 (−3.59, −1.29) 0.09 (0.03, 0.27) <0.001
stage 0–1/stage 2-4 −1.17 (−2.30, −0.03) 0.31 (0.10, 0.97) 0.044 −0.37 (−1.47, 0.73) 0.69 (0.23, 2.07) 0.507
stage 0–2/stage 3-4 0.45 (−0.67, 1.58) 1.57 (0.51, 4.84) 0.432 0.79 (−0.30, 1.89) 2.21 (0.74, 6.61) 0.157
stage 0-3/stage 4 2.96 (1.80, 4.12) 19.32 (6.08, 61.42) <0.001 1.85 (0.74, 2.95) 6.33 (2.10, 19.12) 0.001
Independent variables
Age (year) 0.00 (−0.01, 0.02) 1.00 (0.99, 1.02) 0.665 0.02 (0.00, 0.03) 1.02 (1.00, 1.03) 0.011*
Female to male 0.41 (0.01, 0.82) 1.51 (1.01, 2.27) 0.047* 0.23 (−0.17, 0.63) 1.26 (0.85, 1.88) 0.252
logAFP 0.47 (0.35, 0.59) 1.60 (1.42, 1.81) <0.001* 0.53 (0.40, 0.65) 1.70 (1.50, 1.92) <0.001*
logGGT 0.14 (−0.10, 0.39) 1.15 (0.90, 1.47) 0.259 −0.11 (−0.35, 0.13) 0.90 (0.71, 1.14) 0.363
logAPRI 0.63 (0.43, 0.83) 1.88 (1.54, 2.29) <0.001* 0.36 (0.17, 0.55) 1.43 (1.18, 1.73) <0.001*
*P < 0.05 indicates the corresponding variable was significantly associated to inflammation stage or fibrosis stage. APRI = AST/PLT, AST and ALT were excluded
from both models due to its colinearity to APRI.
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AFP and inflammation when liver inflammation was
more severe.
The specific program of prevention and cure for viral
hepatitis that is generally used in China [19] is similar to
the METAVIR semiquantitative scoring system [23],
and classifies fibrosis into 5 stages: F0 (no fibrosis),
F1 (mild fibrosis without septa), F2 (moderate fibrosis
with few septa), F3 (severe fibrosis with numerous
septa without cirrhosis) and F4 (cirrhosis). CHB patients
with significant fibrosis (METAVIR F >2) are prescribed
antiviral treatment. In the present study, patients at stages
S3 and S4 had a significant elevation in AFP levels, while
patients at stages S0, S1 and S2 had normal AFP values.
The correlation coefficient between AFP and fibrosis
stages was 0.404. AFP levels also showed a moderate
positive trend in relationship to fibrosis stages inTable 5 Summary of the areas under the ROC curves
(AUC) for AFP and APRI
Inflammation Fibrosis
AUC (95% CI) AUC (95% CI)
Judging stage ≥ 2 AFP 0.685 (0.647 - 0.722) 0.691 (0.653 to 0.727)
APRI 0.741 (0.704 - 0.775) 0.687 (0.649 - 0.723)
P-value 0.074 0.897
Judging stage ≥ 3 AFP 0.727 (0.690 - 0.762) 0.717 (0.680 to 0.752)
APRI 0.746 (0.709 - 0.779) 0.649 (0.610 - 0.687)
P-value 0.430 0.007*
Judging stage = 4 AFP 0.755 (0.719 - 0.789) 0.718 (0.681 to 0.753)
APRI 0.714 (0.677 - 0.750) 0.618 (0.578 - 0.656)
P-value 0.221 <0.001*
*P < 0.05 indicate a significant difference between AUCs of AFP and APRI.
ROC, receiver operating characteristic; AUC, area under the curve.CHB patients. Investigation of the relationship between
AFP levels and liver stiffness using transient elastography
showed similar results (correlation coefficient of 0.317
between AFP and fibrosis stages) [8]. These data suggest
that AFP plays a role in regeneration of liver tissue, and
inflammation and liver fibrosis constitute an indirect
index of regeneration. More inflammation is therefore
linked with more regeneration, and more liver fibrosis.
One critical finding of the present study was that serum
AFP levels had a diagnostic value for severity of inflamma-
tion and fibrosis even in patients with “normal” levels of
serum AFP. Low AFP values in some adult patients still
indicated a “severe” condition, reflecting the association
between AFP and liver regeneration.
We previously showed that serum ceruloplasmin (CP)
levels were negatively and indirectly associated with
inflammation and fibrosis, and used serum CP in
combination with routinely measured clinical parameters
to establish a non-invasive model to predict fibrosis [24].
The prognostic value of a number of other biomarkers
for liver fibrosis, such as FibroTest, FibroMeter, FIB-4,
ELF, APRI, and FibroScan elastography, were recently
investigated [25,26], and only the FibroTest had no
significant difference in prognostic value compared to
liver biopsy. There has also been a recent focus on
developing novel proteomic biomarkers candidates for
liver fibrosis in hepatitis C [27]. Although a number of
biomarkers including albumin, platelets, hyaluronic acid
and AST have been evaluated, there is currently no
single marker which successfully predicts significant
fibrosis in HBV-related liver disease, and multiple
biomarkers are needed to complement clinical data [7]. In
the present study, we compared the prognostic value of
AFP with that of liver biopsy, using a METAVIR-like
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between AFP and both inflammation and fibrosis, suggest-
ing that AFP had a prognostic value, especially given the
AUROC scores in our study. The most important criteria
for use of a specific non-invasive biomarker in clinical
practice is the number of patients correctly classified
by the method for a defined end-point based on the
reference standard for the method [9]. Based on these
criteria, AFP is a promising biomarker to assess liver
pathology.
To our knowledge, this is the first study to examine
the relationship between serum AFP levels and the
pathological status of inflammation and fibrosis in
patients with CHB. Nevertheless, this study has some
limitations. First, the study was done in a single medical
center and the sample was relatively small. Second, we
applied the accepted pathological staging system used in
China but there are no known comparisons between this
system and other universal systems, which may limit the
value of our findings. It is important to note that the
occurrence of acute flares has an important role in
the progression of CHB. Differences in inflammation
grade make it difficult to evaluate the performance of
fibrosis biomarkers such as AFP which are strongly influ-
enced by inflammation. Finally, serum AFP values in this
study were measured at certain transverse sections of time
and not dynamically. We are aware that better diagnostic
values for liver pathological stages could be attained by re-
peated and dynamic measurement of AFP levels, and plan
to address this issue in our future studies. Values for
serum ALT and sonography were not included for each
patient, which precludes determining the sensitivity, speci-
ficity and overall effectiveness of serum AFP in compari-
son to other approaches. Future studies with multiple
centers and a larger sample size are needed to evaluate the
prognostic value of adding AFP to the clinical scoring
models currently used [7]. Serum biomarkers have been
shown to contribute only modestly to clinical predictive
factors for risk assessment, indicating that potential
biomarkers must be studied in cohorts with a broad
distribution of fibrosis severity [7].
Conclusion
In conclusion, we showed the subclinical significance of
serum AFP levels by analyzing the association between
serum AFP and different stages of inflammation and
fibrosis. We showed that increasing levels of inflamma-
tion and fibrosis in CHB patients were associated with
increased serum AFP levels. However, there is no single
laboratory parameter that can currently independently
predict the prognosis of liver pathology accurately, and
an important future goal will be to develop a predictive
mathematical model using a combination of different
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